NCT03165890View on ClinicalTrials.gov

Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

July 24, 2017

Study Completion Date

July 24, 2017

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

ACETAZOLAMIDE oral capsule

Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

DRUG

Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m

Trial Locations (1)

720040

National Center of Cardiology and Internal Medicine, Bishkek

All Listed Sponsors
collaborator

National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

OTHER_GOV

lead

University of Zurich

OTHER

NCT03165890 - Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude | Biotech Hunter | Biotech Hunter